throbber
Trials@uspto.gov
`571.272.7822
`
`
`
`
`
`
` Paper No. 11
`
` Entered: September 2, 2016
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`ARKEMA INC. and ARKEMA FRANCE,
`Petitioner,
`
`v.
`
`HONEYWELL INTERNATIONAL INC.,
`Patent Owner.
`____________
`
`Case IPR2016-00643
`Patent 9,157,017 B2
`____________
`
`
`Before MICHAEL P. TIERNEY, GRACE KARAFFA OBERMANN, and
`MICHELLE N. ANKENBRAND, Administrative Patent Judges.
`
`TIERNEY, Administrative Patent Judge.
`
`
`DECISION
`Denying Institution of Inter Partes Review
`37 C.F.R. § 42.108
`
`
`
`
`
`

`
`IPR2016-00643
`Patent 9,157,017 B2
`I.
`INTRODUCTION
`Arkema, Inc. and Arkema France (“Petitioner”), filed a Petition
`
`requesting an inter partes review of claims 1–20 of U.S. Patent 9,157,017
`B2 (Ex. 1001, “the ’017 patent”). Paper 3 (“Pet.”). Patent Owner,
`Honeywell International, (“Patent Owner”) did not file a Preliminary
`Response to the Petition. We have jurisdiction under 35 U.S.C. § 324.
`
`For the reasons set forth below, upon considering the Petition, we
`conclude that the information presented in the Petition fails to establishes a
`reasonable likelihood that the ’017 patent is eligible for inter partes review.
`
`2
`
`

`
`IPR2016-00643
`Patent 9,157,017 B2
`A. Related Proceedings
`The ’017 patent claims the benefit of a series of applications, the
`earliest of which was filed on October 25, 2002. Ex. 1001, 1:5–25. The
`’017 patent priority chain is depicted below:
`
`
`Id. Although Patent Owner has not asserted the ’017 patent in any currently
`pending proceedings, several applications in the priority chain have been
`
`3
`
`

`
`IPR2016-00643
`Patent 9,157,017 B2
`asserted and undergone reexamination. Patent Owner Mandatory Notices,
`Paper 8, 1–3.
`The ’017 patent also has been challenged in PGR2016-00011 and
`PGR2016-00012. Pet. 3.
`
`
`B. The ’017 Patent
`The ’017 patent is directed to the use of fluorine substituted olefins,
`including tetra-, and penta-fluoropropenes, in a variety of applications.
`Ex. 1001, Abstract. For example, the fluorine substituted olefins are
`described as having use in methods of depositing catalysts, sterilizing
`articles, cleaning methods, applying medicaments, fire extinguishing, flavor
`formulations and inflating agents. Id. Although not mentioned in the ’017
`patent abstract, the specification states that a preferred aspect of the
`invention is directed to refrigerant compositions comprising at least one
`multi-fluorinated olefin. Id. at Field of the Invention, 1:29-34.
`Preferred fluorinated substituted olefins include compounds having
`the Formula I, XCFzR3-z, “where X is a C2 or a C3 unsaturated, substituted
`or unsubstituted, alkyl radical, each R is independently Cl, F, Br, I or H, and
`z is 1 to 3.” Id. at 3:45-50. The ’017 patent also states that preferred
`compositions include compounds of Formula II, depicted below:
`
`
`“where each R is independently Cl, F, Br, I or H[,] R' is (CR2)nY, Y is CRF2
`and n is 0 or 1.” Id. at 4:10-21. The patent goes on to state that “[i]n highly
`preferred embodiments, Y is CF3, n is 0 and at least one of the remaining Rs
`
`4
`
`

`
`IPR2016-00643
`Patent 9,157,017 B2
`is F.” Id. at 22–23. Hence, given that R can independently be F, Cl, Br, I or
`H, with at least one R being F, even the highly preferred embodiments of the
`invention according to Formula II encompass a significant number of
`substituted fluoro-propenes. The specification goes on to state that, in
`“certain highly preferred embodiments” the compositions comprise one or
`more tetrafluoropropenes and identifies HFO-1234ze (1,3,3,3-
`tetrafluoropropene) as particularly preferred. Id. at 4:58–63. Of note, the
`specification does not clarify what is meant by “certain” highly preferred
`embodiments comprise tetrafluoropropenes, although the discussion appears
`after a discussion of “highly preferred embodiments” having low toxicity
`where n is zero.
`The compositions of the ’017 patent, “particularly those comprising
`HFO-1234ze,” are said to not have a substantial negative affect on
`atmospheric chemistry with a Global Warming Potential (GWP) of
`preferably less than 500 and an Ozone Depletion Potential (ODP) of not
`greater than 0.05. Id. at 5:38–6:4.
`Low toxicity is said to be an advantageous property and the
`specification states that it was “surprisingly and unexpectedly found that
`certain of the compounds having a structure in accordance with the formulas
`described above [formulas I and II] exhibit a highly desirable low level of
`toxicity compared to other such compounds. Id. at 4:39–43. The
`specification states that “applicants believe that a relatively low toxicity
`level is associated with compounds of Formula II, preferably wherein Y is
`CF3, wherein at least one R on the unsaturated terminal carbon is H, and at
`least one of the remaining Rs is F.” Id. at 4:48–53. The specification goes
`on to state that in highly preferred embodiments, n is zero. Id. at 4:56–58.
`
`5
`
`

`
`IPR2016-00643
`Patent 9,157,017 B2
`Another property of particular importance in many applications is
`lubricant compatibility. Id. at 1:23–24. The specification states that it is
`highly desirable for refrigeration fluids to be compatible with the lubricant.
`Id. at 2:25–27. Lubricants tend to become clogged in evaporator coils and
`reduce system efficiency in the absence of solubility of the lubricant in the
`refrigeration liquid over a wide range of temperatures. Id. at 2:32–42.
`The specification describes a number of potential uses for the
`fluorinated olefin compositions. Heat transfer compositions are
`contemplated and it is generally preferred that refrigerant compositions
`comprise compounds in accordance with Formula I, and more preferably
`with Formula II, and even more preferably HFO-1234ze, in an amount of at
`least 50% by weight and more preferably at least about 70% by weight of
`the composition. Id. at 6:30–40. The ’017 specification states that in “many
`embodiments, it is preferred that the heat transfer compositions of the
`present invention comprise trans-HFO-1234ze.” Id. at 6:40–42. The
`specification also states that refrigerant compositions, especially those in
`vapor compression systems, include a lubricant in an amount from about 30
`to about 50% by weight of the composition. Id. at 6:48–55. Commonly
`used refrigerant lubricants include polyol esters (POEs) and polyalkylene
`glycols (PAGs), silicone oil, mineral oil, alkyl benzenes and poly(alpha-
`olefins). Id. at 6:64-7:3. The specification states that it is believed that
`compositions of the invention are adaptable for use in many existing
`refrigeration systems with or without modification. Id. at 7:4–8. In certain
`embodiments it is preferred to use compositions, particularly compositions
`comprising a substantial proportion of, and in some embodiments consisting
`essentially of trans-HFO-1234ze, as a replacement for existing refrigerants,
`such as HFC-134a. Id. at 7:16–20. The specification further states that:
`
`6
`
`

`
`IPR2016-00643
`Patent 9,157,017 B2
`The present methods, systems and compositions are thus
`adaptable for use in connection with automotive air
`conditioning systems and devices, commercial refrigeration
`systems and devices, chillers, residential refrigerator and
`freezers, general air conditioning systems, heat pumps, and the
`like.
`
`
`Id. at 7:38–43.
`
`
`C. Illustrative Claim
`The ’017 patent contains twenty claims, all of which are challenged
`by Petitioner. All of the claimed methods and compositions require a heat
`transfer composition with a low toxicity refrigerant suitable for use in an
`automobile air conditioning system that consists essentially of 2,3,3,3-
`tetrafluorpropene (HFO-1234yf). Ex. 1049, 6. Additionally, all the claims
`require a lubricant that consists essentially of polyalkylene glycol(s)(PAG).
`Id. Additionally, each claim is directed to a specific heat transfer
`application, automobile air conditioning. Id. Independent claim 1 is
`illustrative of the challenged claims and is reproduced below:
`1. A method for producing an automobile air
`conditioning system for use with 2,3,3,3-tetrafluoropropene
`(HFO-1234yf) comprising:
`(a) providing an automobile vapor compression air
`conditioning system usable with refrigerant 1,1,1,2-
`tetrafluoroethane (HFC-134a) and having at least one
`compressor and at least one condenser; and
`(b) providing a heat transfer composition in said system,
`said heat transfer composition consisting essentially of:
`(i) at least about 50% by weight of a low toxicity
`refrigerant suitable for use in automobile air conditioning
`systems, said refrigerant consisting essentially of HFO-1234yf;
`and
`
`(ii) lubricant consisting essentially of polyalkylene
`glycol(s), and
`
`7
`
`

`
`IPR2016-00643
`Patent 9,157,017 B2
`wherein (1) said condenser is operable with said
`refrigerant in a temperature range that includes 150° F. and (2)
`said system when operating at a condenser temperature of 150°
`F. achieves a capacity relative to HFC-134a of about 1 and a
`Coefficient of Performance (COP) relative to HFC-134a of
`about 1.
`
`
`
`
`
`II. ANALYSIS – Inter Partes Review Eligibility
`A petition for inter partes review shall only be filed after 9 months
`after the grant of a patent, or if a post-grant review is instituted under chapter
`32, the date of the termination of such post-grant review. 35 U.S.C.
`§ 311(c). Similarly, our rules require that, if a patent is a patent described in
`section 3(n)(1) of the Leahy-Smith America Invents Act, a petition must be
`filed no earlier than nine months after the date of the grant of the patent.
`37 C.F.R. § 42.102(a)(1). Leahy-Smith America Invents Act (“AIA”), Pub
`L. No. 112-29, 125 Stat. 284 (2011). AIA section 3(n)(1) describes patents
`that issue from applications “that contain[] or contained at any time . . . a
`claim to a claimed invention that has an effective filing date in Section
`100(i) of title 35, United States Code, that is on or after” “the expiration of
`the 18-month period beginning on the date of the enactment of” the AIA.
`AIA § 3(n)(1). Because the AIA was enacted on September 16, 2011,
`section 3(n)(1) patents are those that issue from applications that at one point
`contained at least one claim with an effective filing date on or after March
`16, 2013, with “effective filing date” having the definition given to it by 35
`U.S.C. § 100(i).
`Petitioner, concurrent with the filing of this inter partes review, filed
`two post-grant reviews, PGR2016-00011 and PGR2016-00012, directed to
`the same claims of the ’017 patent that are challenged here. Based upon the
`
`8
`
`

`
`IPR2016-00643
`Patent 9,157,017 B2
`information presented in the post-grant reviews, we held in the post-grant
`reviews that Petitioner has established that the ’017 patent had an effective
`filing date of March 26, 2014, the filing date of the ’588 application from
`which the ’017 patent issued. Accordingly, based on the evidentiary records
`presented to date in the post-grant reviews, there is a more likely than not
`basis to conclude that the ’017 patent is a section 3(n)(1) patent for which no
`inter partes review may be filed until 9 months after the issuance of the
`patent, or until after the date of termination of the post-grant reviews.
`The ’017 patent issued on October 13, 2015. Ex. 1001. Petitioner
`filed the instant petition on February 22, 2016 and a corrected petition on
`February 26, 2016. As such, the instant petition was filed within 9 months
`of the grant of the ’017 patent and is not eligible for inter partes review.
`35 U.S.C. § 311(c), 37 C.F.R. § 42.102(a)(1).
`
`III. ORDER
`In consideration of the foregoing, it is hereby:
`ORDERED that the Petition is denied as to the challenged claims 1–
`20 of the ’017 patent.
`
`
`
`
`
`
`
`9
`
`

`
`10
`
`IPR2016-00643
`Patent 9,157,017 B2
`
`PETITIONER:
`
`Mark D. Sweet
`Mark J. Feldstein
`Erin M. Sommers
`Charles W. Mitchell
`mark.sweet@finnegan.com
`mark.feldstein@finnegan.com
`erin.sommers@finnegan.com
`charles.mitchell@finnegan.com
`Arkema_PTAB@finnegan.com
`
`PATENT OWNER:
`
`Gregg F. LoCascio
`Eugene Goryunov
`Noah Frank
`glocascio@kirkland.com
`egoryunov@kirkland.com
`noah.frank@kirkland.com
`HON_PTAB_Service@kirkland.com

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket